Novadiscovery is continuing its international expansion by opening a new office in the famous Cambridge Innovation Center in Kendall Square, Boston (Massachusetts). The Lyon-based firm plans to generate the majority of its revenues in the United States over the next 24 months. 

Novadiscovery is now in the same time zone as its clients and future clients. It has also decided to move half of its executive committee across the Atlantic. Moving to the center of the largest cluster of life science firms in the United States “is an important step for Nova and marks the start of an exciting new chapter for the firm,” enthuses co-founder and CEO François-Henri Boissel.

“Novadiscovery’s longstanding goal is to make clinical development much more efficient and to shorten the time needed to get innovative therapies onto the market. To achieve this, we must break into more markets, and what better place to start than the United States!” says co-founder and CEO François-Henri Boissel

When the firm was established in 2010, the co-founders realized that biological knowledge is now so complex that it is no longer possible to compile all the information on a given disease into a single place to improve therapeutic innovation and optimize clinical development. “Today, we have to use mathematical modeling to take full and robust advantage of the wealth of knowledge available to us.” 

The platform they designed provides disease models for laboratories. Once the model has been approved, clinical trial simulations are carried out with virtual patients. With Jinkō, more tests can be done in less time and at lower cost. “Our models are mechanistic models based on knowledge harvested by human beings,” explains François-Henri Boissel. 

Jinkō is a unified platform. It can therefore be used by different members of a clinical development team, and not just by experts in biology.